Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Public ClinicalTrials.gov record NCT03075553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Study identification
- NCT ID
- NCT03075553
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 12 participants
Conditions and interventions
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- HTLV-1 Infection
- Hepatosplenic T-Cell Lymphoma
- NK-Cell Lymphoma, Unclassifiable
- Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Mycosis Fungoides
- Refractory Adult T-Cell Leukemia/Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Mycosis Fungoides
- Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
- Laboratory Biomarker Analysis Other
- Nivolumab Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2017
- Primary completion
- May 28, 2019
- Completion
- May 28, 2019
- Last update posted
- Apr 20, 2020
2017 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03075553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2020 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03075553 live on ClinicalTrials.gov.